Short answer: The Aromasin label gives one dose with no titration: one 25 mg tablet once daily after a meal, for both early and advanced breast cancer. In early breast cancer it follows two to three years of tamoxifen to complete five consecutive years of hormonal therapy. With a strong CYP 3A4 inducer such as rifampicin or phenytoin, the dose is 50 mg once daily after a meal.
This is what the FDA label says. Follow your prescriber. Your prescriber may use a different dose or pace than the label's standard schedule.
What Aromasin is approved for: Aromasin is approved for postmenopausal women with breast cancer: as adjuvant treatment of estrogen-receptor positive early breast cancer after two to three years of tamoxifen, switching to Aromasin to complete five consecutive years of hormonal therapy, and for advanced breast cancer that has progressed after tamoxifen (section 1).
Source
AROMASIN (exemestane) tablets, for oral use, prescribing information and Patient Information. Pfizer (Pharmacia & Upjohn). DailyMed, version published December 25, 2025. DailyMed setid cf066b7a-032a-416c-8d40-15ba581423e3
Aromasin is one 25 mg tablet taken by mouth once daily after a meal (section 2.1).
The Patient Information says to take it 1 time each day after a meal, exactly as your doctor tells you.
The table below is the label's schedule, from the Dosage and Administration section. Numbers are copied exactly; the section is in brackets.
| Situation | Dose | Timing and length |
|---|---|---|
| Early breast cancer, after 2 to 3 years of tamoxifen | 25 mg once daily after a meal | To complete a total of five consecutive years of adjuvant hormonal therapy |
| Advanced breast cancer after tamoxifen | 25 mg once daily after a meal | No length given in section 2 |
| Taken with a strong CYP 3A4 inducer (e.g. rifampicin, phenytoin) | 50 mg once daily after a meal | Section 2.2 dose modification |
The recommended dose in early and advanced breast cancer is one 25 mg tablet once daily after a meal.
Strong CYP 3A4 inducers lower exemestane levels, so with a strong inducer such as rifampicin or phenytoin the recommended dose is 50 mg once daily after a meal.
In early breast cancer, Aromasin is used by women who have had two to three years of tamoxifen and switch to complete five consecutive years of adjuvant hormonal therapy in total.
25-hydroxy vitamin D is checked before starting, and women with low vitamin D receive supplementation.
Women with or at risk of osteoporosis have bone density measured by densitometry at the start of adjuvant treatment, and bone loss is monitored.
Aromasin is not taken with systemic estrogen-containing medicines.
Females who can become pregnant have a pregnancy test within 7 days before starting (Patient Information) and use effective birth control during treatment and for 1 month after the last dose; breastfeeding is avoided for the same period (section 17).
The Aromasin label gives no missed-dose instruction. Ask your doctor or pharmacist what to do if a dose is missed.
For early breast cancer, the label describes switching to Aromasin after two to three years of tamoxifen, to complete a total of five consecutive years of adjuvant hormonal therapy.
In Dose Track you set up Aromasin as a protocol with the dose and schedule your prescriber gave you. A protocol can hold dose steps, each with its own dose and length in days or weeks, so a step-up plan like the one on the label can be entered once and the app moves to the next step on its own. Reminders follow the schedule, and every dose is logged with the date and time, so you can see which step you are on and when your last dose was. The app follows what you enter; it does not choose or change a dose.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.